相关实验视频
Updated: Jul 28, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
甲状腺癌的分子基础和向治疗:进展和机遇
Lizhuo Zhang1, Qingqing Feng2, Jiafeng Wang1
1Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China; Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang 310014, China.
向疗法,包括多氨酸激酶抑制剂,为晚期甲状腺癌 (TC) 提供了新的希望. 研究正在探索新的分子标和个性化医疗方法,以克服治疗耐药性并改善差异化甲状腺癌 (DTC),髓性甲状腺癌 (MTC) 和厌塑性甲状腺癌 (ATC) 的结果.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 甲状腺癌 (TC) 是最常见的内分泌恶性瘤,标准治疗在管理高级或耐火病例方面面临挑战.
- 甲状腺癌 (ATC) 和放射性抗分化甲状腺癌 (RR-DTC) 中的复发和转移是显著的问题.
研究的目的:
- 审查TC的分子基础,并讨论当前和新兴的分子向疗法.
- 探索各种类型的TC的新型治疗点和个性化医疗策略.
主要方法:
- 对分子向药物的全面审查,包括多氨酸激酶抑制剂 (MKIs) 和免疫检查点抑制剂.
- 评估已批准的全身疗法,如伦瓦提尼布,索拉费尼布,卡博赞提尼布,万德塔尼布,塞尔珀卡提尼布,普拉塞提尼布,达布拉费尼布和特拉美提尼布.
- 讨论临床试验中的治疗方法和对向疗法的耐药性机制.
主要成果:
- 一些MKI和组合疗法已被批准或正在开发DTC,MTC和ATC.
- 特定抑制剂在不同的TC亚型中显示出有效性,例如MTC的RET特定抑制剂.
- 抵抗机制需要个性化方法来进行二线治疗.
结论:
- 分子向疗法代表了TC管理的重大进步,提供了新的治疗途径.
- 个性化医疗对于优化治疗策略和克服高级或耐火性甲状腺癌的耐药性至关重要.
- 目前正在进行的针对新型标和临床试验的研究对未来的治疗进展具有前景.
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Tumor Immunotherapy
Cancer
Mitogens and the Cell Cycle

